This seminal work established the foundation for the current consensus that TILs confer favorable outcomes in immunogenic breast cancer subtypes such as TNBC and HER2-positive disease but not in luminal tumors, likely due to inherent differences in immune microenvironment and tumor antigenicity. The gene discussed is ERBB2; the disease is breast carcinoma.